Two startups participating in the incubator program of Health Incubator Helsinki in the Meilahti campus area have great news to tell. Maculaser has received initial funding of 1.2 million euros from investors, and another company, EpiHeart, has secured about 600,000 euros through a crowdfunding round.
“The incubator provides tailored, long-term support for aspiring health tech and med tech companies. We help in concept development, piloting, go-to market strategies and raising funding. We have a wide network and can connect different parties together,” says Christian Lardot, Incubator Leader at Health Incubator Helsinki.
Founded in 2020, the incubator currently has 11 companies developing their business, almost all of which have a university background. With the exception of office rent, the service is free-of-charge for companies. The most recent application round ended on 15 March 2021.
“At the application stage we assess whether there is demand for the innovation, service or product of an applicant company. Is the company’s goal to create something new or to improve existing solutions? It is also important that the team is committed and determined,” says Lardot.
New type of laser therapy prevents blindness
Maculaser has developed and patented a new type of laser therapy to prevent blindness caused by common retinal diseases such as age-related macular degeneration.
“Retinal diseases cost healthcare systems around the world 400 billion euros annually. There are currently no treatments for dry age-related macular degeneration, which affects more than 100 million people, for example. If our technology can be used to delay or prevent blindness, it will have a massive impact at both the individual and the societal level,” says Jani Tirronen, Maculaser’s CEO.